Upstream Bio, Inc. - 8-K Filing
Upstream Bio reported Q1 2026 financial results, showing $36.6 million in R&D expenses (up from $25.8M YoY) and a net loss of $40.6 million compared to $27.3 million for the same period last year. The company has $294.6 million in cash as of March 31, 2026, which is expected to fund operations through 2027. It also highlighted progress on its Phase 3 programs for verekitug in severe asthma and CRSwNP with planned FDA End-of-Phase 2 meetings in mid-2026 and anticipated initiation of Phase 3 trials by Q1 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $UPB